Dyno Therapeutics

Dyno Therapeutics is pioneering an artificial intelligence (AI) powered approach to gene therapy, focusing on designing and optimizing adeno-associated virus (AAV) vectors. The company uses machine learning and quantitative high-throughput in vivo experimentation to invent new ways to design gene vectors, with a particular focus on cell-targeting capsid proteins from AAV, the most widely-used vector for gene therapies. Dyno's team includes world-class molecular and synthetic biologists, protein engineers, and gene therapy scientists working alongside software engineers, data scientists, and AI and machine learning experts. Their goal is to create AI-powered gene therapies that enhance the life-changing potential of gene therapies for millions of patients. Dyno's approach involves building a portfolio of proprietary AAV vectors and working with licensing partners to develop targeted AAV vectors for treatments in a wide range of disease areas and indications. The company's technology aims to improve the vector's ability to safely and precisely deliver gene payloads to intended target cells and tissues, addressing the limitations of naturally occurring vectors in current gene therapies.